《结核病免疫治疗专家共识(2022年版)》要点解读  

The interpretation of the key points of the Expert Consensus on Immunotherapy for Tuberculosis(2022 edition)

作　　者：高雯琬 郭建琼 李同心[1] 韩梅 严晓峰[3] 杨松[3] 唐神结[4] Gao Wenwan;Guo Jianqiong;Li Tongxin;Han Mei;Yan Xiaofeng;Yang Song;Tang Shenjie(Central Laboratory,Chongqing Public Health Medical Center,Chongqing 400036;Department of Infectious Disease,the First Affiliated Hospital of Army Medical University,Chongqing 400032,China;Department of Comprehensive Internal Medicine,Chongqing Public Health Medical Center,Chongqing 400036,China;Beijing Chest Hospital,Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute,Beijing 101149,China)

机构地区：[1]重庆市公共卫生医疗救治中心中心实验室,重庆400036 [2]陆军军医大学第一附属医院感染科,重庆400032 [3]重庆市公共卫生医疗救治中心老年结核病综合内科,重庆400036 [4]首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所,北京101149

出　　处：《结核与肺部疾病杂志》2023年第3期194-197,共4页Journal of Tuberculosis and Lung Disease

基　　金：2022年重庆市科卫联合医学科研项目(2022MSXM149);北京市临床重点专科项目(20201214)。

摘　　要：《2022年全球结核病报告》显示,2021年全球结核病、耐药结核病和结核病死亡患者数量均增长,对WHO终止结核病目标的实现构成了严峻挑战。TB/HIV/COVID-19的三重感染重创了全球结核病防治成果,故全球终止结核病策略的如期实现必将是任重道远。全球结核病疫情的新变化,对结核病治疗提出了新的挑战。虽然敏感结核病和耐药结核病患者的化学药物治疗在缩短疗程和提高疗效等方面取得了较大新进展,但是短程全口服新方案仍未在全球推广使用,一线和二线抗结核药物的不良反应较大,结核病的免疫治疗可能为目前化疗困境提供了新的机遇。作者就《结核病免疫治疗专家共识(2022年版)》要点进行解读,希望对提高结核病治疗成功率发挥一定的积极作用。The Global Tuberculosis Report 2022 showed a simultaneous increase of the numbers of people with tuberculosis disease,drug-resistant TB,or tuberculosis deaths in 2021,which had posed a serious challenge to the realization of the goal of End TB Strategy.Triple infections of TB/HIV/COVID-19 has hit heavily on the global TB control efforts.Therefore,It’s still a long way for us to achieve the global goal of ending TB as scheduled.Novel changes of the global tuberculosis epidemic situation constitutes new challenges for the management of tuberculosis.Although great progress has been made in shortening the course of treatment and improving the medication effectiveness for treating both drug-susceptible and drug-resistant tuberculosis,these new shorter all-oral treatment regimens still have not been rolled out globally,the adverse reactions of the first-line and second-line anti-tuberculosis drugs are still relatively high,while the immunotherapy for tuberculosis may provide a new opportunity for the current dilemma of chemotherapy.Thus,we tried to interpret the key points of the Expert Consensus on Immunotherapy for Tuberculosis(2022 edition)with the hope that it may play a positive role in increasing the treatment success rate of tuberculosis therapy.

关 键 词：结核 免疫疗法 总结性报告(主题) 

分 类 号：R52[医药卫生—内科学] R392[医药卫生—临床医学]